Header Logo

MICHAEL R MIGDEN

TitleAssociate Professor
InstitutionMD Anderson
DepartmentDermatology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chiang E, Stafford H, Buell J, Ramesh U, Amit M, Nagarajan P, Migden M, Yaniv D. Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma. Cancers (Basel). 2023 Apr 25; 15(9). PMID: 37173918; PMCID: PMC10177565.
      Citations:    
    2. Wilmas KM, Patel J, Silapunt S, Doan HQ, Migden MR. The Use of a Dehydrated Complete Human Placental Membrane Allograft for Mohs Surgical Defects of the Nose. Dermatol Surg. 2023 Apr 01; 49(4):343-347. PMID: 36799879.
      Citations:    Fields:    Translation:Humans
    3. Aboul-Fettouh N, Kubicki SL, Chen L, Silapunt S, Migden MR. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. Dermatol Clin. 2023 Jan; 41(1):23-37. PMID: 36410980.
      Citations:    
    4. Migden M, Loquai C, Robert C, Baurain JF, Squittieri N, Arntz R, Dierlamm J, Dr?no B. Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73?weeks. JAAD Int. 2023 Mar; 10:31-33. PMID: 36425794; PMCID: PMC9678756.
      Citations:    
    5. Baig IT, Nguyen QD, Jahan-Tigh RR, Migden MR. Digital Photography for the Dermatologist. Clin Dermatol. 2022 Oct 14. PMID: 36252727.
      Citations:    
    6. Chen OM, Kim K, Steele C, Wilmas KM, Aboul-Fettouh N, Burns C, Doan HQ, Silapunt S, Migden MR. Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. Cancers (Basel). 2022 Jul 30; 14(15). PMID: 35954384; PMCID: PMC9367462.
      Citations:    
    7. Burns C, Kubicki S, Nguyen QB, Aboul-Fettouh N, Wilmas KM, Chen OM, Doan HQ, Silapunt S, Migden MR. Advances in Cutaneous Squamous Cell Carcinoma Management. Cancers (Basel). 2022 Jul 27; 14(15). PMID: 35954316; PMCID: PMC9367549.
      Citations:    
    8. Nguyen QB, Patel J, Migden M. Repair of an Extensive Defect of the Left Central Cheek. Dermatol Surg. 2023 01 01; 49(1):77-79. PMID: 35125443.
      Citations:    Fields:    
    9. Aboul-Fettouh N, Chen L, Silapunt S, Migden MR. Use of PD-1 Inhibitors in the Treatment of Advanced Basal Cell Carcinoma. Dermatol Surg. 2021 11 01; 47(11):1511-1512. PMID: 34699444.
      Citations:    Fields:    Translation:Humans
    10. Aboul-Fettouh N, Chen L, Ma J, Patel J, Silapunt S, Migden M. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. Australas J Dermatol. 2022 Feb; 63(1):36-42. PMID: 34699068.
      Citations: 1     Fields:    Translation:Humans
    11. Lewis K, Farberg AS, Guminski A, Squittieri N, Migden M, Dummer R. Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. Dermatol Ther (Heidelb). 2021 Dec; 11(6):2225-2234. PMID: 34669179; PMCID: PMC8611137.
      Citations: 3     
    12. Wilmas KM, Nguyen QB, Patel J, Silapunt S, Migden MR. Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncol. 2021 Dec; 17(35):4971-4982. PMID: 34608809.
      Citations:    Fields:    Translation:Humans
    13. Aboul-Fettouh N, Morse D, Patel J, Migden MR. Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma. Dermatol Pract Concept. 2021 Nov; 11(Suppl 2):e2021169S. PMID: 34877077; PMCID: PMC8609954.
      Citations: 1     
    14. Doan HQ, Chen L, Nawas Z, Lee HH, Silapunt S, Migden M. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Oncotarget. 2021 Sep 28; 12(20):2089-2100. PMID: 34611482; PMCID: PMC8487719.
      Citations: 2     Fields:    
    15. Aboul-Fettouh N, Patel J, Migden MR. Do Not Mess With Tattoos? Mohs Micrographic Surgery for Basal Cell Carcinoma Within the State of Texas. Dermatol Surg. 2021 09 01; 47(9):1273-1275. PMID: 34448763.
      Citations:    Fields:    Translation:Humans
    16. Rabinowits G, Migden MR, Schlesinger TE, Ferris RL, Freeman M, Guild V, Koyfman S, Pavlick AC, Swanson N, Wolf GT, Dinehart SM. Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innov. 2021 Dec; 1(4):100045. PMID: 34909742; PMCID: PMC8659794.
      Citations:    
    17. Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420. PMID: 34358340; PMCID: PMC10187975.
      Citations:    Fields:    Translation:Humans
    18. Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 08; 9(8). PMID: 34413166; PMCID: PMC8382148.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    19. Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG, Dalle S, Bassukas ID, Puig S. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857. PMID: 34000246.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    20. Paccaly AJ, Migden MR, Papadopoulos KP, Yang F, Davis JD, Rippley RK, Lowy I, Fury MG, Stankevich E, Rischin D. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Adv Ther. 2021 05; 38(5):2365-2378. PMID: 33768419; PMCID: PMC8107152.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    21. Sundaresan S, Migden MR, Silapunt S. Exercise-Induced Vasculitis in a Patient With Negative Ultrasound Venous Reflux Study: A Mimic of Stasis Dermatitis. Cutis. 2021 Feb; 107(2):E10-E11. PMID: 33891846.
      Citations:    Fields:    Translation:Humans
    22. Migden M, Farberg AS, Dummer R, Squittieri N, Hanke CW. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. J Drugs Dermatol. 2021 02 01; 20(2):156-165. PMID: 33538567.
      Citations: 8     Fields:    Translation:HumansCells
    23. Lear JT, Guminski A, Leow LJ, Squittieri N, Migden M, Dummer R. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42?months. J Am Acad Dermatol. 2021 Apr; 84(4):1162-1164. PMID: 33358380.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    24. Amit M, Liu C, Netto Gleber FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177. PMID: 33352413.
      Citations:    Fields:    Translation:Humans
    25. Amit M, Liu C, Gleber-Netto FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Baruch EN, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245. PMID: 33320343.
      Citations: 2     Fields:    Translation:Humans
    26. Aria AB, Rosenbaum LE, Migden MR. Multiple inguinal basal cell carcinomas in the setting of intertrigo. Indian J Dermatol Venereol Leprol. 2020 Jul-Aug; 86(4):469. PMID: 31710000.
      Citations:    Fields:    Translation:Humans
    27. Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A, Ulrich C, Eigentler T. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1). PMID: 32554615; PMCID: PMC7304829.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    28. Tam S, Yao CMKL, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135. PMID: 31804658; PMCID: PMC6902183.
      Citations: 5     Fields:    Translation:Humans
    29. Migden MR, Chandra S, Rabinowits G, Chen CI, Desai J, Seluzhytsky A, Sasane M, Campanelli B, Chen Z, Freeman ML, Ibrahim SF, Khushalani NI, Andria M, Ruiz E. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020 Feb; 16(4):11-19. PMID: 31951149.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    30. Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305. PMID: 31952975; PMCID: PMC7771329.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    31. Ahmed SR, Petersen E, Patel R, Migden MR. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):947-951. PMID: 31524530.
      Citations: 19     Fields:    Translation:Humans
    32. Phadnis SS, Chen L, Wang WL, Migden MR, Zaky W. Disseminated anaplastic pleomorphic xanthoastrocytoma with posttreatment fat necrosis during combined BRAF and MEK inhibitors therapy. Pediatr Blood Cancer. 2019 12; 66(12):e27974. PMID: 31502413.
      Citations:    Fields:    Translation:Humans
    33. Silapunt S, Agwu AV, Migden MR. Severe pretibial myxedema refractory to systemic immunosuppressants. Cutis. 2019 Sep; 104(3):E1-E3. PMID: 31675401.
      Citations:    Fields:    Translation:Humans
    34. Chen L, Silapunt S, Petersen ET, Ahmed SR, Migden MR. Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncol. 2019 Sep; 15(27):3171-3184. PMID: 31382778.
      Citations: 2     Fields:    Translation:HumansAnimals
    35. Sekulic A, Migden MR, Lao CD, Miller C, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, ERIVANCE BCC Investigators, Basset-Seguin N, Garbe C, Gesierich A, Mortier L, Schadendorf D, Hauschild A. Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2019 04 18; 19(1):366. PMID: 30999949; PMCID: PMC6474043.
      Citations: 3     Fields:    
    36. Sundaresan S, Migden MR, Silapunt S. Treatment of Leg Veins for Restless Leg Syndrome: A Retrospective Review. Cureus. 2019 Apr 02; 11(4):e4368. PMID: 31192073; PMCID: PMC6551200.
      Citations: 2     
    37. Chen L, Aria AB, Silapunt S, Migden MR. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatol Surg. 2019 01; 45(1):1-16. PMID: 30045105.
      Citations: 4     Fields:    Translation:Humans
    38. Fedda F, Migden MR, Curry JL, Torres-Cabala CA, Tetzlaff MT, Aung PP, Prieto VG, Ivan D, Myers JN, Nagarajan P. Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. J Cutan Pathol. 2019 Feb; 46(2):152-158. PMID: 30414196.
      Citations: 1     Fields:    Translation:Humans
    39. Aria A, Chen L, Rosenbaum LE, Migden MR. Mohs Micrographic Surgery for the Treatment of Cutaneous Metastases in a Patient With Papillary Thyroid Carcinoma. Dermatol Surg. 2018 11; 44(11):1457-1459. PMID: 29293107.
      Citations: 1     Fields:    Translation:Humans
    40. Yao C, Swaby MG, Migden MR, Silapunt S. A Nodular Hidradenoma of Atypical Location in Pregnancy. Acta Derm Venereol. 2018 Oct 10; 98(9):908-909. PMID: 29856466.
      Citations: 1     Fields:    Translation:Humans
    41. Rosenbaum LE, Migden MR. A Tender Subcutaneous Fluctuant Forehead Nodule: An Unexpected Foray Into the Cranium. Dermatol Surg. 2018 Sep; 44(9):1224-1227. PMID: 29315144.
      Citations:    Fields:    Translation:Humans
    42. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351. PMID: 29863979.
      Citations: 316     Fields:    Translation:HumansCTClinical Trials
    43. Balasubramanyam S, Migden MR, Silapunt S. Venous Treatment of Lipodermatosclerosis to Improve Ambulatory Function. Dermatol Surg. 2018 May; 44(5):749-752. PMID: 28858931.
      Citations: 1     Fields:    Translation:Humans
    44. Chen L, Parsons AM, Aria AB, Ciurea AM, Patel AB, Chan C, Griffin JR, Nguyen TH, Migden MR. Surgical site identification with personal digital device: A prospective pilot study. J Am Acad Dermatol. 2018 Sep; 79(3):520-524. PMID: 29524583.
      Citations:    Fields:    Translation:Humans
    45. Freemyer BD, Migden MR, Silapunt S. Linear terra firma-forme dermatosis of the midline back. Cutis. 2018 Mar; 101(3):205-206. PMID: 29718014.
      Citations:    Fields:    Translation:Humans
    46. Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, Tiu RV, Pitou C, Tucker T, Brail L, Von Hoff D. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091. PMID: 29483143; PMCID: PMC6422158.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    47. Li JY, Silapunt S, Migden MR, McGinness JL, Nguyen TH. Mohs Mapping Fidelity: Optimizing Orientation, Accuracy, and Tissue Identification in Mohs Surgery. Dermatol Surg. 2018 Jan; 44(1):1-9. PMID: 28654580.
      Citations: 1     Fields:    Translation:Humans
    48. English CA, Chen L, Migden MR. Traction haemostasis. Australas J Dermatol. 2018 May; 59(2):156-157. PMID: 29243226.
      Citations:    Fields:    Translation:Humans
    49. Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev. 2018 Mar; 64:1-10. PMID: 29407368.
      Citations: 14     Fields:    Translation:Humans
    50. Chen L, Aria AB, Silapunt S, Lee HH, Migden MR. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018 Mar; 14(6):515-525. PMID: 29119833.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    51. Rosales Santillan M, ATajnert K, Swaby MG, Migden MR, Silapunt S. Multiple eccrine spiradenomas in a zosteriform pattern. Dermatol Online J. 2017 Aug 15; 23(8). PMID: 29469747.
      Citations:    Fields:    Translation:Humans
    52. Sundaresan S, Migden MR, Silapunt S. Stasis Dermatitis: Pathophysiology, Evaluation, and Management. Am J Clin Dermatol. 2017 Jun; 18(3):383-390. PMID: 28063094.
      Citations: 6     Fields:    Translation:Humans
    53. Sekulic A, Migden MR, Lao CD, Miller C, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, ERIVANCE BCC Investigators, Basset-Seguin N, Garbe C, Gesierich A, Mortier L, Schadendorf D, Hauschild A. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 05 16; 17(1):332. PMID: 28511673; PMCID: PMC5433030.
      Citations: 87     Fields:    Translation:HumansCellsCTClinical Trials
    54. Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. J Am Acad Dermatol. 2017 Jul; 77(1):55-62.e3. PMID: 28392293.
      Citations: 2     Fields:    Translation:Humans
    55. Wu W, Chavez-Frazier A, Migden M, Nguyen T. The Buried Half Horizontal, Half Vertical Mattress Suture: A Novel Technique for Wound Edges of Unequal Lengths. Dermatol Surg. 2016 Dec; 42(12):1391-1393. PMID: 27427995.
      Citations: 2     Fields:    Translation:Humans
    56. Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124. PMID: 27764798; PMCID: PMC5342800.
      Citations: 5     Fields:    Translation:HumansCells
    57. Migden M. Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome. Lancet Oncol. 2016 12; 17(12):1631-1632. PMID: 27838223.
      Citations:    Fields:    Translation:Humans
    58. Doan HQ, Silapunt S, Migden MR. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. Onco Targets Ther. 2016; 9:5671-5678. PMID: 27695345; PMCID: PMC5028081.
      Citations: 9     
    59. Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 09 01; 11(1):120. PMID: 27581207; PMCID: PMC5007799.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    60. Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601. PMID: 27574101; PMCID: PMC5013636.
      Citations: 50     Fields:    Translation:HumansAnimals
    61. Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016 Sep; 8(5):375-82. PMID: 27583029; PMCID: PMC4981290.
      Citations: 8     
    62. Chen L, Silapunt S, Migden MR. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016 Sep; 12(18):2095-105. PMID: 27189494.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    63. Guminski A, Gutzmer R, Dirix L, Lewis KD, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR, Dummer R, Combemale P, Schulze HJ, Corn?lis F. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5. PMID: 27067394.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    64. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, ERIVANCE BCC investigators, Hauschild A. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8. PMID: 25981002.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    65. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Plummer R, Chang AL, Lear JT, Sellami D, Schulze HJ, Corn?lis F, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28. PMID: 25981810.
      Citations: 120     Fields:    Translation:HumansCTClinical Trials
    66. Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2. PMID: 25935097.
      Citations: 7     Fields:    Translation:Humans
    67. Sharpe HJ, Pau G, Dijkgraaf GJ, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ, Basset-Seguin N. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 09; 27(3):327-41. PMID: 25759019; PMCID: PMC5675004.
      Citations: 148     Fields:    Translation:HumansCells
    68. Lim L, Nichols B, Migden MR, Rajaram N, Reichenberg JS, Markey MK, Ross MI, Tunnell JW. Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis. J Biomed Opt. 2014; 19(11):117003. PMID: 25375350; PMCID: PMC4222134.
      Citations: 27     Fields:    Translation:Humans
    69. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol. 2013 Jul; 52(7):856-61. PMID: 23675612.
      Citations: 2     Fields:    Translation:Humans
    70. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9. PMID: 22670903; PMCID: PMC5278761.
      Citations: 415     Fields:    Translation:HumansCellsCTClinical Trials
    71. Rajaram N, Reichenberg JS, Migden MR, Nguyen TH, Tunnell JW. Pilot clinical study for quantitative spectral diagnosis of non-melanoma skin cancer. Lasers Surg Med. 2010 Dec; 42(10):716-27. PMID: 21246575; PMCID: PMC3059518.
      Citations: 36     Fields:    Translation:Humans
    72. Migden M, Chavez-Frazier A, Nguyen T. The use of high definition video modules for delivery of informed consent and wound care education in the Mohs Surgery Unit. Semin Cutan Med Surg. 2008 Mar; 27(1):89-93. PMID: 18486030.
      Citations: 10     Fields:    Translation:Humans
    73. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome. Orphanet Journal of Rare Diseases. 11.
    74. The Buried Half Horizontal, Half Vertical Mattress Suture. Dermatologic Surgery. 42:1391-1393.
    75. In vivo determination of optical properties and fluorophore characteristics of non-melanoma skin cancer.
    76. Oncotarget. 7:76118-76124.
    77. Sonidegib for the treatment of advanced basal cell carcinoma. Future Oncology. 12:2095-2105.
    78. Reconstruction of the Ears. 135-145.
    79. Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome. The Lancet Oncology. 17:1631-1632.
    80. Mohs' micrographic surgery of the periorbital area. 571-587.
    81. Hedgehog pathway inhibition in advanced basal cell carcinoma. Therapeutic Advances in Medical Oncology. 8:375-382.
    82. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT). Journal of the American Academy of Dermatology.
    83. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. OncoTargets and Therapy. 9:5671-5678.
    84. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nature Communications. 7.
    MIGDEN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (219)
    Explore
    _
    Co-Authors (34)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _